Prestige Wealth Management Group’s Bio-Techne TECH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$495 Sell
7
-35
-83% -$1.89K ﹤0.01% 1034
2026
Q1
$2.19K Hold
42
﹤0.01% 723
2025
Q4
$2.47K Hold
42
﹤0.01% 723
2025
Q3
$2.34K Buy
42
+35
+500% +$1.88K ﹤0.01% 711
2025
Q2
$361 Sell
7
-15
-68% -$754 ﹤0.01% 958
2025
Q1
$1.29K Hold
22
﹤0.01% 811
2024
Q4
$1.58K Hold
22
﹤0.01% 817
2024
Q3
$1.76K Hold
22
﹤0.01% 802
2024
Q2
$1.58K Hold
22
﹤0.01% 770
2024
Q1
$1.55K Hold
22
﹤0.01% 804
2023
Q4
$1.7K Buy
+22
New +$1.45K ﹤0.01% 779
2022
Q3
Sell
-4
Closed 1065
2022
Q2
$0 Hold
4
﹤0.01% 1067
2022
Q1
$0 Hold
4
﹤0.01% 1047
2021
Q4
$1K Hold
4
﹤0.01% 953
2021
Q3
$0 Hold
4
﹤0.01% 1049
2021
Q2
$0 Hold
4
﹤0.01% 1033
2021
Q1
$0 Buy
+4
New +$365 ﹤0.01% 1036
2020
Q2
Sell
-16
Closed -$1K 957
2020
Q1
$1K Buy
+16
New +$800 ﹤0.01% 845
2019
Q1
Sell
-44
Closed -$2K 1066
2018
Q4
$2K Buy
+44
New +$1.84K ﹤0.01% 876

Other funds holding TECH

Prestige Wealth Management Group's TECH Position: Q2 2026 in Review

Prestige Wealth Management Group reduced its Bio-Techne (TECH) stake by 83% in Q2 2026, selling an estimated $1.89K and leaving 7 shares worth $495. The position accounts for ﹤0.01% of the portfolio, ranked #1034.

Prestige Wealth Management Group first reported a position in TECH in Q4 2018 and has held it in 19 quarters since. The position peaked at $2.47K in Q4 2025. 596 funds tracked by Wall St. Rank hold TECH as of Q2 2026.

  • Prestige Wealth Management Group held 7 shares of Bio-Techne worth $495 as of Q2 2026.
  • Prestige Wealth Management Group sold 35 Bio-Techne shares in Q2 2026, an estimated $1.89K.
  • Bio-Techne made up ﹤0.01% of Prestige Wealth Management Group's portfolio in Q2 2026, its #1034 holding.
  • Prestige Wealth Management Group first reported a position in Bio-Techne in Q4 2018 and has held it in 19 quarters since.
  • Prestige Wealth Management Group's Bio-Techne position peaked at $2.47K in Q4 2025.
  • 596 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2026.

Based on Prestige Wealth Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.